NCT04370587View on ClinicalTrials.gov

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

September 22, 2026

Study Completion Date

January 10, 2027

Conditions
Solid TumorMelanomaHNSCCSarcomaSquamous Cell CarcinomaNSCLC
Interventions
BIOLOGICAL

T3011

T3011 will be administered up to 4mL as an intratumoral injection given Q2W.

COMBINATION_PRODUCT

T3011 + pembrolizumab

T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.

Trial Locations (9)

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

85234

COMPLETED

Banner MD Anderson Cancer Center, Gilbert

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Unknown

RECRUITING

Southern Oncology, Bedford Park

RECRUITING

Peninsula & South Eastern Haematology and Oncology Group, Frankston

RECRUITING

The Alfred, Melbourne

All Listed Sponsors
lead

ImmVira Pharma Co. Ltd

INDUSTRY